Conclusions Male breast cancer survivors experience substantial symptoms Hormonal symptoms are prevalent in male breast cancer survivors; in men without cancer, mean EPIC Hormonal Score is 91.7 (SD 9.7) Sexual functioning may be impaired in male breast cancer survivors; in men without cancer, mean EPIC Sexual Score is 61.4 (SD 23.6) We plan to use data from this pilot study to inform a larger study and develop targeted interventions to reduce symptom burden in male breast cancer survivors Kathryn J. Ruddy, MD MPH, 1 Anita Giobbie-Hurder, MS, 1 Sharon Giordano, MD, 2 Shari Goldfarb, MD, 3 Sandra Kereakoglow, BA, 1 Eric P. Winer, 1 MD, Ann H. Partridge, MD MPH 1 1 Dana-Farber Cancer Institute, Boston, MA; 2 M.D. Anderson Cancer Center, Houston, TX; 3 Memorial Sloan Kettering Cancer Center, New York, NY Physical and Psychological Sequelae of Breast Cancer in Men Background Little is known about the physical and emotional health of men with breast cancer; data are also lacking regarding their informational and supportive care needs Aim To assess attitudes, symptoms, experiences, and health perceptions in men with a history of breast cancer Methods Study Setting Online survey recruiting participants via three websites focused on male breast cancer: Measurements Anxiety and depression over prior month using Hospitalized Anxiety and Depression Scale (HADS), scored 0-21 for each subscale Health-related quality of life (QOL) over prior 7 days using Functional Assessment of Cancer Therapy-Breast (FACT-B), scored Hormonal and sexual symptoms over prior 4 weeks using the Expanded Prostate Cancer Index Composite (EPIC) Hormonal and Sexual Scales, each scored Higher scores on the HADS indicate more symptoms; higher scores on FACT-B and EPIC imply better QOL History of genetic and fertility counseling Limitations Potential for sample bias, recall bias, and unmeasured confounders Hormonal SymptomsN=36 One or more hot flashes per week 4 (11%) Breast tenderness at least once per week 6 (27%) Depressed at least once per week 17 (47%) Lack of energy at least once per week 27 (75%) Weight gain 11 (31%) Sexual SymptomsN=37 “Poor” or “very poor” sexual desire 21 (57%) “Poor” or “very poor” ability to have erection 18 (49%) “Poor” or “very poor” ability to reach orgasm 13 (35%) Erection not adequate for intercourse 20 (54%) Erections not whenever desired 26 (70%) Never awakened with erection 11 (30%) No sexual activity 13 (35%) No sexual intercourse 25 (68%) “Poor” or “very poor” ability to function sexually24 (65%) “Moderate” or “big” problem with sexual desire 16 (43%) “Moderate” or “big” problem with erection 16 (43%) “Moderate” or “big” problem with orgasm 11 (30%) “Moderate” or “big” problem with sexual functioning 17 (46%) Genetic Counseling/TestingN=41 Referred for genetic counseling or testing Had genetic testing Tested positive for hereditary cancer syndrome 31 (74%) 25 3 Fertility Issues N=42 No biological children 10 (24%) Desire future biological children 2 (5%) Informed about risks to fertility from treatment 3 (7%) Stored sperm 1 (2%) Distress and Quality of LifeN=38 Anxious (HADS Anxiety >10) 3 (8%) Depressed (HADS Depression >10) 2 (5%) EPIC Hormonal Score; Mean (SD) 81.3 (15.5) EPIC Sexual Score; Mean (SD) 44.5 (26.3) FACT-B Total Score; Mean (SD) (19.9) Respondent CharacteristicsN=42 Median age in years (range) 64 (25-80) Median years since diagnosis (range) 1.8 ( ) Stage at diagnosis N (%) 0 3 (7%) 1 10 (24%) 2 15 (36%) 3 6 (14%) 4 4 (10%) Unknown 4 (10%) Have had a cancer other than breast cancer 14 (33%) Cancer-free at time of survey 32 (74%) Caucasian 41 (98%) College/Post-college graduate 31 (74%) Married or “living as married” 31 (74%) Employed (full or part time) 14 (33%) Stopped work for at least one month during treatment 7 (17%) Financially comfortable (i.e., has “$ for special things”) 22 (52%) Medically insured 41 (98%) Before diagnosis, exercised less than once a week 9 (21%) Reduced exercise since diagnosis 9 (21%) Received chemotherapy 26 (62%) Had mastectomy (uni- or bilateral) 38 (90%) Received radiation 10 (24%) Currently taking tamoxifen 19 (45%) Currently taking gonadotropin-releasing hormone agonist 1 (2%) Currently taking aromatase inhibitor 5 (12%)